vs
Side-by-side financial comparison of NEUROCRINE BIOSCIENCES INC (NBIX) and PLEXUS CORP (PLXS). Click either name above to swap in a different company.
PLEXUS CORP is the larger business by last-quarter revenue ($1.2B vs $814.5M, roughly 1.4× NEUROCRINE BIOSCIENCES INC). NEUROCRINE BIOSCIENCES INC runs the higher net margin — 24.3% vs 4.3%, a 20.0% gap on every dollar of revenue. On growth, NEUROCRINE BIOSCIENCES INC posted the faster year-over-year revenue change (42.2% vs 18.7%). Over the past eight quarters, NEUROCRINE BIOSCIENCES INC's revenue compounded faster (17.5% CAGR vs 7.2%).
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Plex Systems, Inc. is an American software company based in Troy, Michigan. The company develops and markets the Plex Manufacturing Cloud, a software as a service (SaaS) or cloud computing ERP for manufacturing.
NBIX vs PLXS — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $814.5M | $1.2B |
| Net Profit | $197.9M | $49.8M |
| Gross Margin | 98.3% | 10.2% |
| Operating Margin | 23.7% | 5.3% |
| Net Margin | 24.3% | 4.3% |
| Revenue YoY | 42.2% | 18.7% |
| Net Profit YoY | — | 27.5% |
| EPS (diluted) | $1.91 | $1.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $814.5M | — | ||
| Q1 26 | — | $1.1B | ||
| Q4 25 | $805.5M | — | ||
| Q3 25 | $794.9M | — | ||
| Q2 25 | $687.5M | — | ||
| Q1 25 | $572.6M | — | ||
| Q4 24 | $627.7M | — | ||
| Q3 24 | $622.1M | — |
| Q2 26 | $197.9M | — | ||
| Q1 26 | — | $41.2M | ||
| Q4 25 | $153.7M | — | ||
| Q3 25 | $209.5M | — | ||
| Q2 25 | $107.5M | — | ||
| Q1 25 | $7.9M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $129.8M | — |
| Q2 26 | 98.3% | — | ||
| Q1 26 | — | 9.9% | ||
| Q4 25 | 97.8% | — | ||
| Q3 25 | 98.2% | — | ||
| Q2 25 | 98.4% | — | ||
| Q1 25 | 98.4% | — | ||
| Q4 24 | 98.5% | — | ||
| Q3 24 | 98.7% | — |
| Q2 26 | 23.7% | — | ||
| Q1 26 | — | 5.1% | ||
| Q4 25 | 26.2% | — | ||
| Q3 25 | 30.1% | — | ||
| Q2 25 | 21.2% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 29.5% | — |
| Q2 26 | 24.3% | — | ||
| Q1 26 | — | 3.8% | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 26.4% | — | ||
| Q2 25 | 15.6% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 20.9% | — |
| Q2 26 | $1.91 | — | ||
| Q1 26 | — | $1.51 | ||
| Q4 25 | $1.49 | — | ||
| Q3 25 | $2.04 | — | ||
| Q2 25 | $1.06 | — | ||
| Q1 25 | $0.08 | — | ||
| Q4 24 | $1.00 | — | ||
| Q3 24 | $1.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $303.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.4B | $1.5B |
| Total Assets | $4.9B | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | $248.8M | ||
| Q4 25 | $713.0M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $264.0M | — | ||
| Q1 25 | $194.1M | — | ||
| Q4 24 | $233.0M | — | ||
| Q3 24 | $349.1M | — |
| Q2 26 | $3.4B | — | ||
| Q1 26 | — | $1.5B | ||
| Q4 25 | $3.3B | — | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $2.7B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.7B | — |
| Q2 26 | $4.9B | — | ||
| Q1 26 | — | $3.2B | ||
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.3B | — | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $3.7B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.5B | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBIX
| INGREZZA Net Product Sales | $656.9M | 81% |
| CRENESSITY Net Product Sales | $153.3M | 19% |
| Other Revenues | $4.3M | 1% |
PLXS
| Asia-Pacific | $652.0M | 56% |
| Americas | $397.0M | 34% |
| Europe, Middle East and Africa | $116.0M | 10% |
